Reprogramming T Cells to Cross the Brain’s Border

One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T cells to transport bispecific therapeutic payloads across the blood-brain barrier and into other targeted tissue with an initial focus on treating glioblastoma. We spoke to Michael Roberts, co-founder and CEO of Adaptin Bio, about the unmet need in glioblastoma, the limitations of current blood-brain barrier–crossing strategies, and how the company’s platform seeks to change the treatment paradigm by using patient-derived T cells as delivery vehicles for targeted biologics.

You can listen to Reprogramming T Cells to Cross the Brain’s Border online on Radio and Podcast. Open the player on this page to stream the available audio.

Reprogramming T Cells to Cross the Brain’s Border is an episode from The Bio Report by Levine Media Group.

This episode is 38:47 long.

This episode was published on Feb 4, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.